Communication for Professional Investors in Austria, Switzerland, Germany, Spain, United Kingdom, Italy, Luxembourg, the Netherlands, Singapore, and Portugal.



Courtesy of Midjourney

# The AI Agents have arrived!

### APERTURE EUROPEAN INNOVATION FUND

Q2 2024 | MANAGER QUARTERLY COMMENTARY





**Dear Clients and Investors,** 

In this quarter's investment note, we examine the resilience of Equities against a backdrop of economic uncertainty and political turbulence. Despite inflation concerns and electoral shocks, the MSCI Europe Net Total Return index achieved a modest gain of 1.32%.

We spotlight the unprecedented surge in AI innovation, marked by a flurry of groundbreaking announcements from tech giants and startups alike. Of particular note is the emergence of AI Agents and Micro-Agents, heralding new capabilities in reasoning and planning that is reminiscent of the revolutionary impact of the iPhone's debut.

These rapid advancements are reshaping industries at an accelerating pace, potentially offering significant opportunities for investors.

As we navigate through market volatility, we will explore key trends, notable performers and our strategic outlook for capitalising on this transformative wave of innovation.

Wishing you a wonderful summer ahead.

Best Regards,

Anis Lahlou CIO, European Equities



#### Performance<sup>1</sup>

	RETURNS AS OF JUNE 30, 2024 (%, net of fees)									
	MTD	QTD	YTD	2023	2022	2021	2020	Annualised Since Inception		
Fund <sup>2</sup>	1.10	1.83	15.47	18.90	-16.21	28.73	11.13	11.75		
Benchmark <sup>3</sup>	-0.98	1.32	9.05	15.83	-9.49	25.13	-3.32	7.46		
Relative Performance	2.08	0.51	6.42	3.07	-6.72	3.60	14.45	4.29		

<sup>\*</sup> Past performance is not a reliable indicator of future performance and can be misleading. Since Inception figures are annualized. Annual past performance related to ISIN LU2077746936. Performance is net of all fees except entry and exit fees (where applicable). Dividend reinvested for accumulative classes. Past performance is calculated in EUR.

#### Inflation sways, equities weather election shock while AI continues to surge!

The MSCI Europe Net Total Return index ended the quarter up 1.32%, despite the return of volatility induced by the French elections. June marked the worst relative performance for European equities compared to US stocks since the start of the Ukraine conflict, with mid-single-digit losses. This halted but did not cancel the enthusiasm for European equities, in our opinion (see the outlook section). Increased risk aversion weighed on cyclical stocks, with Consumer, Bank, Construction and Automotive sectors underperforming relative to defensive parts of the market. Small Caps performed broadly in line with Large Caps, though with volatility between May (M7EUSC +2.57% vs M7EU) and June (-2.36%). Risk-off was also visible in crypto, with Bitcoin recording a -15% drop from its March highs.

As for inflation, the pendulum of worries about sticky inflation data kept markets on edge early in the quarter. However, as per the recent pattern, later data in the quarter showed that the economy's soft landing should broadly remain on track. As observed, April's worse-than-expected US inflation figures triggered a nearly 3-5% drop in major indices, leading investors to reassess and delay anticipated Fed rate cuts. The month of May brought a sigh of relief with inflation meeting expectations and dovish tones from the ECB, leading to a market rebound. June further solidified the easing rhetoric with US CPI at 0.16% m/m, the lowest in 33 months. The ECB, aligning with global peers like Canada, Sweden, and Switzerland, announced its first rate cut since 2020, lowering the deposit rate by 25bp to 3.75%, aiming to stabilize economic growth and market sentiment.

Finally, and importantly in our view, the AI Boom shows no signs of slowing down, in fact we feel it was quite the opposite: Nvidia led the charge again as its market capitalization surpassed the \$3 trillion mark, fuelled by Q1 revenues well ahead of expectations, growing 262% year-over-year and 18% quarter-over-quarter. The Q2 guidance,

<sup>&</sup>lt;sup>1</sup> Past performance does not predict future returns. Where the reference currency of the fund differs than yours, returns and costs may increase or decrease as a result of currency and exchange rate fluctuations. This is not an exhaustive list of the costs. Other costs apply and differ per share class.

<sup>&</sup>lt;sup>2</sup> The Fund = The Aperture European Innovation Fund (ticker APEIIED LX). Share Class Inception Date = 2019-12-17.

<sup>&</sup>lt;sup>3</sup> Benchmark = the Fund's Benchmark, MSCI Europe Net Total Return EUR Index (ticker MSDEE15N Index). Indices are unmanaged and do not include the effect of fees. One cannot invest directly in an index. The performance of the Benchmark does not predict future performances of that Benchmark and of the performance of the Fund. The fund is actively managed and references the Benchmark only for the purpose of performance fee calculation. The Investment Manager has full discretion over the composition of the Fund's portfolio and therefore its composition may deviate substantially from the Benchmark so as to take advantage of specific investment opportunities.



which also came above consensus both on revenue and EPS, pointed to further acceleration in its datacentre segment going into H2, firmly pointing to demand exceeding supply well into next year.

We continue to see this trend benefiting stock picking in European equities significantly, particularly in the semiconductor and semiconductor equipment ecosystem, and more broadly in all manufacturing and services industries, Healthcare, and small caps. We discuss this more in detail in the outlook section.

#### MSCI Europe (M7EU Index) : Q2 Performance Map



Source: Bloomberg.

#### How did we do this quarter?

The Aperture European Innovation Fund (Ticker: APEIIED LX) closed the quarter up **+1.83%** (**net of fees**), or **+0.51%** ahead of its benchmark MSCI Europe Net Total Return Index, shrugging the volatility mentioned above, with a marginally positive Stock Selection effect.

#### Single stock commentary

#### AI and Obesity verticals driving Stock Selection once again.

Top contributors to portfolio performance included AI-exposed semiconductor equipment companies **ASM International** (ASM NA), and **ASML** (ASML NA), but also leading German ERP Software company **SAP** (SAP GY). Obesity



was also a feature, with our top contributing stocks including both **Zealand Pharma** (ZEAL DC) and **Novo Nordisk** (NOVOB DC).

**ASM International**, a key player in semiconductor equipment manufacturing, saw its stock price increase by 26% during Q2. This rise was triggered by a strong Q1 performance, with order intake 3-6% above forecasts, driven by high demand for 2nm Gate-All-Around and High Bandwidth Memory technologies.

Similarly, **ASML**, the world-leading supplier of lithography equipment essential for producing both cutting-edge and mature integrated circuits (see more in the outlook section), experienced an 11% stock price increase in June. This was fuelled by optimistic management comments during a group call about potential 2nm-related orders from TSMC. Management also expressed confidence in aiming for the upper end of their 2025 guidance.

**SAP**'s stock price rose by 14% in June, boosted by upbeat comments from Management at its Sapphire event, its major annual conference attended by the SAP ecosystem of integrators and customers. Management highlighted resilient demand but also confidently hinting at accelerating revenue growth and margin expansion between 2025 and 2027. The stock also rose 3.5% on June 12, benefiting from stronger-than-expected bookings reported by its US peer, Oracle.

**Nvidia** remains a position in the fund albeit outside of our top 10. Nvidia stock price gained 27% in May and 37% over Q2, reporting robust Q1 results with increasing customer demand across enterprise verticals and consumer internet hyperscalers. Data Center revenue exceeded expectations by 6%, driven by strong compute demand and continued strong H100 shipments, alleviating concerns about a potential slowdown in this segment in the transition to Blackwell systems.

**Zealand Pharma**, the Danish biotech company, saw its stock price increase by 35% since June 20 following the announcement of positive headline data from its highly anticipated Phase 1b trial of the amylin analogue, Petrelintide, for Obesity. Petrelintide showed promising results for both weight reduction and safety/tolerability.

**Novo Nordisk**'s stock gained 14% during Q2 as the stock price of the leading Danish GLP1 drug manufacturer continues to find support in strong prescription growth particularly in the US and strong deployment of capacity, which should in our view keep driving positive earnings surprises.

#### Stocks that detracted.

Detractors included stocks that de-rated amidst sticky inflation and higher rates concerns. Such was the case with payment companies **Adyen** (ADYEN NA) and **Wise** (WISE LN). Detractors also unsurprisingly included stocks in France such as **GTT** (GTT FP), **Capgemini** (CAP FP) and **Sopra Steria** (SOP FP) which indiscriminately came under pressure after the election shockwaves in France.

**Adyen** saw its shares decrease by 28% in April, erasing its year-to-date gains. Despite reporting robust volume growth in Q1, Adyen's net revenue fell slightly below expectations due to a lower-than-expected take and a negative customer mix effect.

Shares in **Wise**, a UK based provider of software solutions handling international multi-currency money transfers, lost 11% on June 13<sup>th</sup> after the company issued a medium-term outlook seen below consensus expectations due to anticipated price reductions and increased marketing expenses.

French Engineering group **GTT**, saw its stock price lose 11% during the quarter. There was no fundamental news to explain this move; the stock drifted due to a lack of fresh buying interest following Engie's sale of its remaining stake at the end of Q1. Additionally, French small and mid-cap stocks faced significant pressure since June 9<sup>th</sup> due to political uncertainty following President Macron's decision to organize new parliamentary elections.



French based IT Service providers **Capgemini** and **Sopra Steria** also faced challenges from the political news in France, along with persistent doubts about whether the H2 acceleration guided by most sector participants will materialise after a number of read-across news and industry data pointed to deterioration, Numeum, the professional association for the digital sector in France, revised its growth forecast for the industry in 2024 to 5.0% down from 5.8% previously.

#### What have we done?

We had entered 2024 with a low exposure to Value. This was because our innovation stock picking pointed us more towards companies with much stronger pricing power, typically exhibiting higher quality traits and trading at higher price multiples. We have been on the look-out for stock picking opportunities in the Value camp last quarter and added stocks in Financials and Energy and we built on these positions to add new stocks such as **Barclays PLC** (BARC LN) and **GALP** (GALP PL).

New additions to the portfolio this quarter were mostly in the quality/compounding camp that, we believe are not too expensive and were funded by more expensive names, marginally improving the fund's Value exposure overall.

New additions included **AstraZeneca** (AZN LN), based on expectations of positive pipeline catalysts in oncology and expectations of a more favourable earnings outlook ahead of its Q1 reporting. We also initiated a position in **Iberdrola** (IBE SM), where we believe the company's medium-term targets are yet to be fully reflected in consensus estimates, with further upside potential from the development of the network business, to which the bulk of the company's capex will be allocated.

These purchases were funded by selling what we considered to be expensive names such as **LVMH** (MC FP), **Adyen** (ADYEN NA) and **Lonza** (LONN SW).

#### How do we think about the outlook?

#### Inflation driven macro-volatility and election shock: Noise v. Opportunities


While inflation concerns and French elections caused short-term volatility, we believe these issues will resolve over time, similar to past political shifts in Italy and the Netherlands. The upcoming US election may bring additional turbulence in Q3.

We want to balance our focus to take into consideration large opportunities: the potential from cash deployment as interest rates normalise is massive (chart below).



### Cash on the sidelines

Over \$6 trillion of cash sitting is US money market funds



Finally, it is our view that the AI revolution (below), presents too significant a potential to ignore amidst short-term market noise.

#### AI Agents have arrived: Unprecedented Innovation Surge in Major Announcements

This past quarter has witnessed an extraordinary wave of AI innovation, each individually rivalling the revolutionary impact of the iPhone's debut in magnitude. Tech giants and startups alike have unleashed a flurry of announcements, each pushing AI capabilities to new frontiers.

OpenAI's GPT-40, Google's Gemini 1.5 Flash and Project Astra, Microsoft's Copilot Plus PCs, Anthropic Claude 3.5 Sonnet, and Apple's Intelligence initiative represent, each and in isolation, leaps in AI technology. These advancements introduce emotion recognition, real-time translation, and seamless AI integration into hardware, software ecosystems, and daily apps.

Most crucially, they herald new capabilities in reasoning and planning, now referred to as AI Agents and Micro-Agents. In fact, Nvidia's NIMS (Nvidia Inference Micro Services) is democratising a full infrastructure of agents through "Micro Agents," potentially catalysing widespread AI Agent deployment across industries. We are watching this space closely.

In eCommerce, Amazon is introducing Rufus (named of the company's mascot, see below) as its new AI Agent/Shopping Assistant. Meta is beta-testing AI Agents in its Whatsapp business activity in India and Singapore.





**Rufus is an Amazon legend.** He's an adorable corgi that used to roam the halls of Amazon's HQ. He was the pet of their principal engineer and was found roaming the halls and chasing tennis balls. Today he is the inspiration of Amazon's new, generative AI Agent shopping assistant.

Source: Analyticindex.com

In Healthcare, Color Health's application of GPT-40 is a new AI Agent for cancer treatment planning. Google DeepMind's AlphaFold 3, capable of generating 3D structures of biological molecules, demonstrates AI's profound real-world impact.

#### AI Acceleration: The New Normal

With equity markets soaring and five major tech companies – Nvidia, Alphabet, Microsoft, Meta, and Amazon – driving performance (with Nvidia alone contributing nearly 30% of this year's gains), the sustainability of this rally is a key debate. However, Nvidia's trajectory so far aligns with its fundamental shift from a gaming GPU company to an AI factory powerhouse. The \$1 trillion datacentre market presents a vast opportunity, and Nvidia is poised to capture the lion share.

We anticipate AI innovation to accelerate further. While Moore's Law predicts computing power doubling every two years, the CPU to GPU shift is outpacing this. Model optimization yields 10-10,000x improvements over a model's lifetime, suggesting potential 10 or 30x capability enhancements in the near future. This may also explain the recent flood of AI announcements and may become the new norm that we have to get used to!

Notably, these model breakthroughs occurred without substantial increases in computational power for individual models. Most new models, including Meta Llama 3, Google Gemini Ultra, and Anthropic's 3.5 Sonnet, operate at roughly the GPT-4 level (2e25 FLOP).

The inevitable emergence of 2e30 FLOP models sometime soon and the 10-30x model optimization improvements ahead of us suggest significant growth potential in AI capabilities. This makes it hard to imagine how we should not expect further AI acceleration. This also makes it hard to believe how this growth will only be contained to Nvidia alone or a few Magnificent Stocks in the US.

#### ASML High NA (watch the video below!): How European Innovation is pioneering the future of Generative AI

ASML's High NA technology (Narrow Aperture – a name we are so glad to share with ASML's leading technology) marks a revolutionary leap in semiconductor manufacturing, pivotal not just for the company but for the broader generative AI landscape. High NA represents the next generation of EUV (extreme ultraviolet) lithography, enabling a dramatic increase in the density and precision of microchip patterning—achieving features sizes 2.9 times denser with enhanced resolution (from 0.33 to 0.55x magnification). This technology allows for greater productivity and overlay accuracy while reducing energy consumption, cycle times, and patterning defects among many other benefits.



Currently in its R&D phase with Intel in Oregon, mass production is slated for 2027. The underlying EUV technology, crucial for crafting AI supercomputer chips, relies on an intricate process where tin droplets are bombarded by lasers in a vacuum—a method essential to prevent light absorption by air. This process is showcased in a recently released ASML video, illustrating the complex engineering required to produce these advanced chips.



Source: ASML on YouTube

Central to ASML's success is its European ecosystem, including specialised suppliers like Switzerland's Inficon and VAT Group, who provide critical components such as vacuum gauges and high-performance valves. These components are integral to maintaining the precise conditions needed for EUV lithography. This network of innovation underscores Europe's crucial role in the AI compute ecosystem, reinforcing the idea that just as generative AI is unimaginable without Nvidia, it is equally dependent on ASML and its collaborative European infrastructure.



We aim to capitalise on the transformative adoption curves in AI through our behavioural stock selection approach, all while maintaining a balanced approach to risk management. We hold a very optimistic outlook on the opportunities that lie ahead.





### HAVE A FAB EUROPEAN SUMMER!

Enjoy the Euro2024 and Paris Olympics




#### **Risk Profile of European Innovation Fund**

Lower ris	sk		Higher risk				
Potential	lly lower r	ewards		Potentially higher rewards			
1	2	3	4	5	6	7	

The Risk and Reward profile of this Sub-fund, as reflected in the Summary Risk Indicator ("SRI") required for the PRIIPS KID is 4. The SRI is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you. The SRI for this product is 4 out of 7, which is a medium class. Risk 1 does not mean a risk-free investment. This indicator may change over time.

\*It should be noted that the calculation of the SRI has been derived from the return history of the Fund in accordance with the prescribed PRIIPS methodology given the sub-fund has over 3 years of historical daily returns data available. In accordance with the associated guidelines for UCITS, the calculation of the Synthetic Risk and Reward Indicator (SRRI) in the KIID has been derived from a representative portfolio model, target asset mix or benchmark given we do not have 5 years of historical returns data for the fund on which to apply the prescribed calculations.

Inherent risks of the Sub-fund include: Sustainable finance risk, Market risk, Volatility risk, Equity, Investment in smaller companies, Foreign exchange, Short exposure risk, Derivatives, OTC financial derivative instruments, Rule 144A and/or Regulation S securities, Sustainability risk.





#### IMPORTANT INFORMATION

Investments involve risks. Past performance does not predict future return. There can be no assurance that an investment objective will be achieved or that there will be a return on capital. You may not get back the amount initially invested. Before making any investment decision, investors must read the Prospectus, and particularly the Risk Factors, as well as the Key Information Document (KID) or Key Investor Information Document (KIID) as applicable to their jurisdiction.

Costs: (illustrative class: ISIN LU2077746936 – registered in AT, CH, DE, ES, IT, LU, PT, UK): Entry charge: up to 3% max, Exit charge: none, Ongoing charge: 0.65% per year. Performance fee: For its services to the Sub-fund, the Investment Manager is entitled to a variable management fee ("VMF"), which is calculated and accrued daily, at a rate of 2.85% (the "VMF Midpoint"). The VMF Minimum portion of the VMF will be calculated and accrued daily based on the Sub-fund's NAV. The rest of the VMF amount, if any, will be calculated and accrued daily based on the Sub-fund's daily Modified Net Assets, adjusted upward or downward by a performance adjustment (the "Performance Adjustment") that depends on whether, and to what extent, the performance of the Sub-fund exceeds, or is exceeded by, the performance of the Benchmark plus 8.5% (850 basis points) (the "VMF Midpoint Hurdle") over the Performance Period. For a full description of the VMF please see the applicable section in Appendix A contained in the Prospectus.

This marketing communication is related to **Aperture Investors SICAV**, an open-ended investment company with variable capital (SICAV) under Luxembourg law of 17 December 2010, qualifying as an undertaking for collective investment in transferable securities (UCITS) and its Sub-Fund, European Innovation Fund altogether referred to as "the Fund". This marketing communication is intended **only for professional investors** in **Austria**, **Switzerland, Germany, Spain, United Kingdom, Italy, Luxembourg, the Netherlands, Singapore and Portugal,** where the Fund is registered for distribution, within the meaning of the Markets in Financial Instruments Directive 2014/65/EU (MiFID) and **is not intended for retail investors**. The Fund has not been registered under the United States Investment Company Act of 1940, as amended, and is **not intended for U.S. Persons** as defined under Regulation S of the United States Securities Act of 1933, as amended.

This document is co-issued by Aperture and Generali Asset Management S.p.A. Società di gestione del risparmio, Generali Investments Luxembourg S.A. and Aperture.


Aperture Investors UK Ltd is authorized as Investment Manager in the United Kingdom, regulated by the Financial Conduct Authority (FCA) - 135-137 New Bond Street, London W1S 2TQ, United Kingdom – UK FCA reference n.: 846073 – LEI: 549300SYTE7FKXY57D44. Aperture Investors, LLC is authorized as investment adviser registered with the U.S. Securities and Exchange Commission ("SEC") which wholly owns Aperture Investors UK, Ltd, altogether referred as "Aperture". Aperture Investors, LLC draws upon the portfolio management, trading, research, operational and administrative resources of certain of its affiliates (at the present, Aperture UK), including using affiliates to execute transactions for certain Funds. Subject to the written consent of the applicable Fund and the regulatory status of the affiliate, Aperture Investors, LLC treats these affiliates as "participating affiliates," in accordance with applicable SEC no-action letters and guidance. For a more complete understanding of Aperture's ownership and control, please see our ADV available here: https://adviserinfo.sec.gov/

The Management Company of the Fund is Generali Investments Luxembourg S.A., a public limited liability company (société anonyme) under Luxembourg law, authorised as UCITS Management Company and Alternative Investment Fund Manager (AIFM) in Luxembourg, regulated by the Commission de Surveillance du Secteur Financier (CSSF) - CSSF code: S00000988 LEI: 222100FSOH054LBKJL62.

Generali Asset Management S.p.A. Società di gestione del risparmio is an Italian asset management company regulated by Bank of Italy and appointed to act as marketing promoter of the Fund in the EU/EEA countries where the Fund is registered for distribution (Via Niccolò Machiavelli 4, Trieste, 34132, Italia - C.M. n. 15376 - LEI: 549300DDG9IDTO0X8E20).

Please also consider all the ESG characteristics, approach, binding elements of the selection process and methodological limits contained in the SFDR Pre-contractual annex of the prospectus, as well as the Summary of the Website Product Disclosure, available in the "Sustainability-related Disclosure" section of the website fund page at: <a href="www.generali-investments.lu">www.generali-investments.lu</a>. Before making any investment decision, please read the **Key Information Document** (KID) or **Key Investor Information Document (KIID)** (as applicable to your jurisdiction) and the **Prospectus**. The KIDs are available in one of the official languages of the EU/EEA country, where the Fund is registered for distribution, and the Prospectus is available in English (not in French), as well as the annual and semi-annual reports at <a href="www.generali-investments.lu">www.generali-investments.lu</a> or upon request free of charge to Generali Investments Luxembourg SA, 4 Rue Jean Monnet, L-2180 Luxembourg, Grand Duchy of Luxembourg, e-mail address: <a href="mailto:GILfundInfo@generali-invest.com">GILfundInfo@generali-invest.com</a>. The Management Company may decide to terminate the agreements made for the marketing of the Fund. For a summary of **your investor rights** in respect of an individual complaint or collective action for a dispute relating to a financial product at the European level and at the level of your EU country of residence, please consult the information document contained in the "About Us" section at the following link: <a href="www.generali-investments.com">www.generali-investments.lu</a>. The summary is available in English or in a language authorized in your country of residence.

In the United Kingdom: The Fund is a recognised scheme. This document is a financial promotion, approved for the purposes of Section 21 of the Financial Services and Markets Act 2000, by Aperture Investors UK, Ltd. The regulation for the protection of retail clients in the United Kingdom and the





compensation available under the UK Financial Services Compensation scheme does not apply in respect of any investment or services provided by an overseas person.

In Switzerland: The Fund is registered with the Swiss Financial Market Supervisory Authority (FINMA). Advertising intended for Swiss qualified investors as Article 10 (3) and (3ter) of the Collective Investment Schemes Act (CISA), meaning: (1) Swiss professional and Swiss institutional investors as per Article 4 paragraphs 3–5 of Federal Act on Financial Services (FinSA) and Article 5 paragraphs 1-4 (including High-Net-Worth individuals) (2) Retail investors for whom a financial intermediary provides portfolio management or investment advice under the conditions defined in Article 10 (3ter) of CISA. The Swiss version of the prospectus and KIIDs are available at <a href="https://www.generali-investments.lu">www.generali-investments.lu</a>. Swiss Representative: ACOLIN Fund Services AG, Leutschenbachstrasse 50 CH 8050 Zurich - Swiss Paying agent: InCore Bank AG, Wiesenstrasse 17 P O Box, CH 8952 Schlieren.

In the Middle East:

Kuwait

This fact sheet is not for general circulation to the public in Kuwait. The Fund has not been licensed for offering in Kuwait by the Kuwait Capital Markets Authority or any other relevant Kuwaiti government agency. The offering of the Fund in Kuwait on the basis a private placement or public offering is, therefore, restricted in accordance with Law No. 7 of 2010 (the Kuwait Capital Markets Law) (as amended) and the bylaws thereto (as amended). No private or public offering of the Fund is being made in Kuwait, and no agreement relating to the sale of the Fund will be concluded in Kuwait. No marketing or solicitation or inducement activities are being used to offer or market the Fund in Kuwait.

Qatar

UAE

The materials contained herein are not intended to constitute an offer, sale or delivery of shares of the Fund or other financial products under the laws of Qatar. The Fund has not been and will not be authorised by the Qatar Financial Markets Authority, the Qatar Financial Centre Regulatory Authority or the Qatar Central Bank in accordance with their regulations or any other regulations in Qatar. The shares of the Fund are not and will not be traded on the Qatar Stock Exchange.

Saudi Arabia

The Capital Market Authority does not make any representation as to the accuracy or completeness of this document, and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorised financial adviser.

In accordance with the provisions of the United Arab Emirates (UAE) Securities and Commodities Authority's (SCA) Board Decision No. (9/R.M) of 2016 Concerning the Regulations as to Mutual Funds, the units in the Fund to which this document relates may only be promoted in the UAE as follows: (1) without the prior approval of SCA, only in so far as the promotion is directed to financial portfolios owned by federal or local governmental agencies; (2) investors following a reverse enquiry; or (3) with the prior approval of the SCA. The approval of the SCA to the promotion of the Fund units in the UAE does not represent a recommendation to purchase or invest in the Fund. The SCA has not verified this document or other documents in connection with this Fund and the SCA may not be held liable for any default by any party involved in the operation, management or promotion of the Fund in the performance of their responsibilities and duties, or the accuracy or completeness of the information in this document. The Fund units to which this document relates may be illiquid and/or subject to restrictions on their resale. Prospective investors should conduct their own due diligence on the Fund. If you do not understand the contents of this document, you should consult an authorised financial advisor.

This marketing communication is not intended to provide an investment, tax, accounting, professional or legal advice and does not constitute an offer to buy or sell the Fund or any other securities that may be presented. Any opinions or forecasts provided are as of the date specified, may change without notice, may not occur and do not constitute a recommendation or offer of any investment. Past or target performance do not predict future returns. There is no guarantee that positive forecasts will be achieved in the future. The value of an investment and any income from it may go down as well as up and you may not get back the full amount originally invested. The future performance is subject to taxation, which depends on the personal situation of each investor and which may change in the future. Please liaise with your Tax adviser in your country to understand how your returns will be impacted by taxes. The existence of a registration or approval does not imply that a regulator has determined that these products are suitable for investors. It is recommended that you carefully consider the terms of investment and obtain professional, legal, financial and tax advice where necessary before making a decision to invest in a Fund.

**Generali Investments is a trademark** of Generali Asset Management S.p.A. Società di gestione del risparmio, Generali Insurance Asset Management S.p.A. Società di gestione del risparmio, Generali Investments Luxembourg S.A. and Generali Investments Holding S.p.A. - Sources (unless otherwise specified): **Aperture and Generali Asset Management S.p.A. Società di gestione del risparmio** - This document may not be reproduced (in whole or in part), circulated, modified or used without prior written permission.

MSCI. The MSCI information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for or a component of any financial instruments or products or indices. None of the MSCI information is intended to constitute investment advice or a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such. Historical data and analysis should



## Aperture European Innovation Q2 Manager Quarterly Commentary

not be taken as an indication or guarantee of any future performance analysis, forecast or prediction. The MSCI information is provided on an "as is" basis and the user of this information assumes the entire risk of any use made of this information. MSCI, each of its affiliates and each other person involved in or related to compiling, computing or creating any MSCI information (collectively, the "MSCI Parties") expressly disclaims all warranties (including, without limitation, any warranties of originality, accuracy, completeness, timeliness, non-infringement, merchantability and fitness for a particular purpose) with respect to this information. Without limiting any of the foregoing, in no event shall any MSCI Party have any liability for any direct, indirect, special, incidental, punitive, consequential (including, without limitation, lost profits) or any other damages. (www.msci.com)

#### Investors should note the specific risk warnings:

Equity Risk: The strategy will be affected by changes in the stock markets and changes in the value of individual portfolio securities. At times, stock markets and individual securities can be volatile, and prices can change substantially in short periods of time. The equity securities of smaller companies are more sensitive to these changes than those of larger companies. This risk will affect the value of the strategy, which will fluctuate as the value of the underlying equity securities fluctuates.

<u>Investment in Smaller Companies Risk:</u> Investment in smaller companies may involve greater risks and thus may be considered speculative. Many small company stocks trade less frequently and in smaller volumes and may be subject to more abrupt or erratic price movements than stocks of larger companies. The securities of small companies may also be more sensitive to market changes than securities in large companies.

<u>Short Exposure Risk:</u> The strategy may proceed with short-term sales of their investment via the use of derivatives. The short exposure risk results from short sales achieved through the use of derivatives and includes the potential for losses exceeding the cost of the investment, as well as the risk that the third party to the short sale will not fulfil its contractual obligations.

Derivatives Risk: The strategy may use derivative instruments, such as options, futures and swap contracts and enter into forward foreign exchange transactions. The ability to use these strategies may be limited by market conditions and regulatory limits and there can be no assurance that the objective sought to be attained from the use of these strategies will be achieved. Participation in the options or futures markets, in swap contracts and in foreign exchange transactions involves investment risks and transaction costs to which the strategy would not be subject if it did not use these strategies. If Aperture's predictions of movements in the direction of the securities, foreign currency and interest rate markets are inaccurate, the adverse consequences to the strategy may leave the strategy in a less favorable position than if such strategies were not used. Risks inherent in the use of options, foreign currency, swaps and futures contracts and options on futures contracts include, but are not limited to (a) dependence on the Aperture's ability to predict correctly movements in the direction of interest rates, securities prices and currency markets; (b) imperfect correlation between the price of options and futures contracts and options thereon and movements in the prices of the securities or currencies being hedged; (c) the fact that skills needed to use these strategies are different from those needed to select portfolio securities; (d) the possible absence of a liquid secondary market for any particular instrument at any time; and (e) the possible inability of the strategy to purchase or sell a portfolio security at a time that otherwise would be favorable for it to do so, or the possible need for the strategy to sell a portfolio security at a disadvantageous time. Where the strategy enters into swap transactions it is exposed to a potential counterparty risk. In case of insolvency or default of the swap counterparty, such event would affect the assets of the strategy.

Rule 144A and Regulation S Risk: SEC Rule 144A provides a safe harbor exemption from the registration requirements of the US Securities Act of 1933 for resale of restricted securities to qualified institutional buyers, as defined in the rule. Regulation S provides an exclusion from registration requirements of the US Securities Act of 1933 for offerings made outside the United States by both US and foreign issuers. A securities offering, whether private or public, made by an issuer outside of the United States in reliance on Regulation S need not be registered. The advantage for investors may be higher returns due to lower administration charges. However, dissemination of secondary market transactions is limited and might increase the volatility of the security prices and, in extreme conditions, decrease the liquidity of a particular security.

IPO Risk: The market value of shares issued in an IPO may fluctuate considerably due to factors such as the absence of a prior public market, unseasoned trading, the small number of shares available for trading and limited information about a company's business model, quality of management, earnings growth potential, and other criteria used to evaluate its investment prospects. Accordingly, investments in IPO shares involve greater risks than investments in shares of companies that have traded publicly on an exchange for extended periods of time. Investments in IPO shares may also involve high transaction costs, and are subject to market risk and liquidity risk, which are described elsewhere in this section.

For further information on risks related to the Fund please see the Prospectus.